



## ASX ANNOUNCEMENT

31 March 2025

### Non-executive Director Changes

---

**31 March 2025** – Cann Group Limited (ASX: CAN) (**Cann** or the **Company**) is pleased to announce the appointment of Mr. Peter Kopanidis as Non-executive Director of Cann, effective 31 March 2025. Mr. Robert Barnes is retiring as a Non-executive Director of Cann also effective 31 March 2025.

Peter has over 30 years of experience as a finance professional in a broad range of industries, including manufacturing, telecommunications, healthcare, insurance, financial services and FMCG. Most recently, Peter has held senior executive roles leading investor relations, corporate treasury, and corporate finance at Medibank, Telstra, Treasury Wine Estates and Foster's Group. He is a Director and owner of Petra Investor Relations & Debt Advisory Pty Ltd, a service provider to ASX-listed companies. Peter is a Chartered Accountant and holds a Bachelor of Business – Accounting, he started his career as an Auditor at KPMG.

Robert Barnes has served on the Cann Board as a Non-executive Director since 20 September 2022. Rob has been a valuable contributor to the Board, particularly with his pharmaceutical background as Cann navigates the regulated special access scheme and authorised prescriber landscape.

Doug Rathbone, Chair of the Cann Group Board, said "First, I want to acknowledge Rob for his dedication over the past two and a half years, during which Cann has faced numerous challenges. Rob has played a valuable role in evaluating key issues and offering his insights. Secondly, I'm excited to welcome Peter to the Board. His extensive experience in debt advisory, corporate finance, and investor relations will be invaluable to the Company, especially at this critical stage and moving forward."

-ENDS-

**Authorised for release by Steven Notaro, Company Secretary, Cann Group Limited.**

**For all information please contact:**

Jenni Pilcher  
CEO & Managing Director  
Cann Group Limited  
+61 3 9095 7088  
[contact@canngrouponlimited.com](mailto:contact@canngrouponlimited.com)

Steven Notaro  
Company Secretary  
Cann Group Limited  
+61 3 9095 7088  
[contact@canngrouponlimited.com](mailto:contact@canngrouponlimited.com)

**About Cann Group**

Cann Group Limited (ABN 25 603 949 739) is enhancing patients' lives by developing, producing, and supplying innovative cannabis medicines. The Company has research facilities and corporate headquarters in Melbourne and operates a state-of-the-art large-scale cultivation and GMP manufacturing facility near Mildura, Victoria. Cann Group supplies a range of dried flower and oil products, as well as active pharmaceutical ingredients and extracts, to customers in Australia and around the world. Cann Group also owns Satipharm and its patent-protected capsule technology.

Learn more at: [www.canngrouponlimited.com](http://www.canngrouponlimited.com) | [www.satipharm.com](http://www.satipharm.com)